Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.
暂无分享,去创建一个
Krister Wennerberg | Hassan Al-Ali | Jae K Lee | Prson Gautam | Houssam Nassif | David H Drewry | Vance P Lemmon | John L Bixby | J. Bixby | K. Wennerberg | D. Drewry | Houssam Nassif | H. Al-Ali | V. Lemmon | Prson Gautam | Do-Hun Lee | Matt C Danzi | Bill Zuercher | Do-Hun Lee | Jae K. Lee | M. Danzi | B. Zuercher
[1] Stephan C. Schürer,et al. Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets , 2013, J. Chem. Inf. Model..
[2] Chris H. Q. Ding,et al. Minimum redundancy feature selection from microarray gene expression data , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.
[3] K. Jacobson,et al. Phosphorylation of paxillin by p 38 MAPK is involved in the neurite extension of PC-12 cells , 2004 .
[4] L. Mosyak,et al. Structure-based optimization of PKCθ inhibitors , 2007 .
[5] Stephan C. Schürer,et al. Kinome-wide activity models from diverse high-quality datasets , 2013 .
[6] James S. Duncan,et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.
[7] K. Jacobson,et al. Phosphorylation of paxillin by p38MAPK is involved in the neurite extension of PC-12 cells , 2004, The Journal of cell biology.
[8] David Page,et al. Relational Differential Prediction , 2012, ECML/PKDD.
[9] Do-Hun Lee,et al. Mammalian Target of Rapamycin's Distinct Roles and Effectiveness in Promoting Compensatory Axonal Sprouting in the Injured CNS , 2014, The Journal of Neuroscience.
[10] K. Schlingensiepen,et al. Inhibition of P185(C-ERBB-2) protooncogene expression by antisense oligodeoxynuleotides down regulates P185 associated tyrosine kinase activity and strongly inhibits mammary tumor cell proliferation , 1994 .
[11] S. Strittmatter,et al. Axonal growth therapeutics: regeneration or sprouting or plasticity? , 2008, Trends in Neurosciences.
[12] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[13] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[14] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[15] John L. Bixby,et al. High content screening of cortical neurons identifies novel regulators of axon growth , 2010, Molecular and Cellular Neuroscience.
[16] Stephan C Schürer,et al. Chemical interrogation of the neuronal kinome using a primary cell-based screening assay. , 2013, ACS chemical biology.
[17] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[18] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[19] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[20] W. Young. Spinal Cord Regeneration , 1996, Science.
[21] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[22] Helmut Mack,et al. Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.
[23] M. Heisenberg,et al. P90 Ribosomal s6 kinase 2 negatively regulates axon growth in motoneurons , 2009, Molecular and Cellular Neuroscience.
[24] Simon K. Mencher,et al. BMC Clinical Pharmacology BioMed Central Debate , 2005 .
[25] S. Günther,et al. Targeting the BET family for the treatment of leukemia. , 2014, Epigenomics.
[26] Pierre E Ilouga,et al. High Content Screening Analysis in R , 2013 .
[27] J. Schwab,et al. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar , 2003, Molecular and Cellular Neuroscience.
[28] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[29] O. Steward,et al. Advances in the Management of Spinal Cord Injury , 1998, The Journal of the American Academy of Orthopaedic Surgeons.
[30] Yishi Jin,et al. S6 Kinase Inhibits Intrinsic Axon Regeneration Capacity via AMP Kinase in Caenorhabditis elegans , 2014, The Journal of Neuroscience.
[31] Zhigang He,et al. PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration , 2004, Nature Neuroscience.
[32] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[33] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[34] Albert-László Barabási,et al. Controllability of complex networks , 2011, Nature.
[35] K. Strebhardt,et al. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs , 2007, Oncogene.
[36] B. Tang,et al. Axonal regeneration in adult CNS neurons – signaling molecules and pathways , 2006, Journal of neurochemistry.
[37] Kaj Blennow,et al. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers , 2013, Nature Reviews Neurology.
[38] Vance P Lemmon,et al. Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphology , 2010, Molecular systems biology.
[39] L. Tsai,et al. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. , 1996, Genes & development.
[40] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.
[41] Xiao-Ming Xu,et al. Cortical PKC inhibition promotes axonal regeneration of the corticospinal tract and forelimb functional recovery after cervical dorsal spinal hemisection in adult rats. , 2014, Cerebral cortex.
[42] G. Terstappen,et al. Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.
[43] R. Huber,et al. Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.
[44] G. Superti-Furga,et al. Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.
[45] P. Nicotera,et al. Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen , 2008, Cell Death and Differentiation.
[46] S. Okuno. Mammalian target of rapamycin inhibitors in sarcomas , 2006, Current opinion in oncology.
[47] Krister Wennerberg,et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.
[48] L. Benowitz,et al. Combinatorial treatments for promoting axon regeneration in the CNS: Strategies for overcoming inhibitory signals and activating neurons' intrinsic growth state , 2007, Developmental neurobiology.
[49] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[50] Garry P Nolan,et al. What's wrong with drug screening today. , 2007, Nature chemical biology.
[51] S. Frantz. Drug discovery: Playing dirty , 2005, Nature.
[52] T. Willson,et al. Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS) , 2014, Current topics in medicinal chemistry.
[53] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[54] K. Kaestner,et al. KLF Family Members Regulate Intrinsic Axon Regeneration Ability , 2009, Science.
[55] Aideen Long,et al. Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.